ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
Research presented at ASM Microbe has revealed that Treg cells may be protecting babies from contracting HIV from their mothers in utero.
The US FDA and the European Medicines Agency are investigating reports of neural tube defects in babies born to women on GlaxoSmithKline’s antiretroviral drug dolutegravir.
A new study has highlighted the neurological damage caused by exposure to HIV without antiretroviral therapy.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
New research has suggested that a protein involved in Alzheimer’s disease may also be implicated in HIV-associated neurological disorders, suggesting Alzheimer’s therapies may benefit a subset of HIV patients.
Mylan N.V have announced they’ll be launching their third HIV combination in the US, following FDA approval of their once-daily treatment Symfi™.
